Precigen, Inc. (NASDAQ:PGEN)
| Market Cap | $1.51B+10.2% |
| Revenue (ttm) | $156.94M+2387.6% |
| Net Income | $24.41M+109.9% |
| EPS | $0.04+102.7% |
| Shares Out | 358.55M |
| PE Ratio | 61.64 |
| Forward PE | 6.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,067,718 |
| Open | $4.16 |
| Previous Close | $4.16 |
| Day's Range | $4.07 - $4.36 |
| 52-Week Range | $3.04 - $8.98 |
| Beta | 0.98 |
| Analysts | Buy |
| Price Target | $15.00(+256.29%) |
| Earnings Date | Mar 24, 2027 |
About PGEN
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating PGEN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 24, 2027Earnings report
$PGEN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PGEN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PGEN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PGEN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PGEN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PGEN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PGEN
| VTIVanguard Morningstar Total Stock Market ETF | $31.91M |
| XBIState Street SPDR S&P Biotech ETF | $24.19M |
| IWMiShares Russell 2000 ETF | $21.78M |
| VXFVanguard Extended Market ETF | $15.02M |
| VTWOVanguard Russell 2000 ETF | $7.88M |
| IWOiShares Russell 2000 Growth ETF | $7.53M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from PGEN’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong Q3 earnings with 37% revenue growth and early positive cash flow achievement outweigh new buy rating; concrete business momentum dominates.
Recent Insider Activity
Insider Score Trend Over Time
+29.0 since Sep 20Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| ADDS | Hedgeye Index Adds ETF | 1.41% |
| BBP | Virtus Biotech ETF | 1.36% |
| GRNJ | Fundstrat Granny Shots US Small- & Mid-Cap ETF | 1.22% |
| PCSG | Polen 5Perspectives Small-Mid Growth ETF | 0.56% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.39% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.35% |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | 0.30% |
| XBI | State Street SPDR S&P Biotech ETF | 0.27% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.24% |
| IWC | iShares Micro-Cap ETF | 0.22% |
| OASC | OneAscent Enhanced Small and Mid Cap ETF | 0.17% |
| FYX | First Trust Small Cap Core AlphaDEX Fund | 0.16% |
Weight is the stock’s share of each fund’s holdings.
